Fujirebio was established in 1950 and specializes in the development diagnostic biomarkers for identifying metabolic, neurodegenerative, and infectious diseases as well as cancer. Fujirebio is currently recruiting for a clinical trial (NCT03174938) that will evaluate the safety and efficacy of a diagnostic biomarker it has developed for detecting Alzheimer’s disease in blood.